Whereas safety and efficacy of HPV vaccines in healthy women have been shown in several randomised controlled clinical trials and in post marketing analyses, only few data exist in patients affected by autoimmune diseases. These issues are significant as autoimmune conditions are recognised as a risk factor for the persistence of HPV infection. Herein we review and systematise the existing literature to assess immunogenicity and safety of HPV vaccination in patients with autoimmune diseases, including systemic lupus erythematosus and juvenile idiopathic arthritis. The results of our literature revision suggest that the HPV vaccines are efficacious and safe in most of the patients affected by autoimmune diseases. Yet, some points of concern remain to be tackled, including the effects of concomitant therapies, the risk of disease exacerbation and the cost-effectiveness of such immunisation programmes in these populations.

Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases : a systematic review / P. Pellegrino, S. Radice, E. Clementi. - In: VACCINE. - ISSN 0264-410X. - 33:30(2015 Jul 09), pp. 3444-3449. [10.1016/j.vaccine.2015.05.041]

Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases : a systematic review

P. Pellegrino
Primo
;
S. Radice
Secondo
;
E. Clementi
Ultimo
2015

Abstract

Whereas safety and efficacy of HPV vaccines in healthy women have been shown in several randomised controlled clinical trials and in post marketing analyses, only few data exist in patients affected by autoimmune diseases. These issues are significant as autoimmune conditions are recognised as a risk factor for the persistence of HPV infection. Herein we review and systematise the existing literature to assess immunogenicity and safety of HPV vaccination in patients with autoimmune diseases, including systemic lupus erythematosus and juvenile idiopathic arthritis. The results of our literature revision suggest that the HPV vaccines are efficacious and safe in most of the patients affected by autoimmune diseases. Yet, some points of concern remain to be tackled, including the effects of concomitant therapies, the risk of disease exacerbation and the cost-effectiveness of such immunisation programmes in these populations.
Autoimmune diseases; Cost-effectiveness; HPV vaccines; Safety
Settore BIO/14 - Farmacologia
9-lug-2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0264410X15006933-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 607.91 kB
Formato Adobe PDF
607.91 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/327443
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 17
social impact